Sarilumab治疗风湿性多肌痛的有效性和安全性:FIRST注册的回顾性研究

IF 2.1 4区 医学 Q3 RHEUMATOLOGY
Naoaki Ohkubo, Yusuke Miyazaki, Satoshi Kubo, Ippei Miyagawa, Koshiro Sonomoto, Yoshino Inoue, Yurie Satoh-Kanda, Hiroaki Tanaka, Masanobu Ueno, Atsushi Nagayasu, Takafumi Aritomi, Ryuichiro Kanda, Yuya Fujita, Masashi Funada, Hidenori Sakai, Kiyotake Yoshioka, Mayu Nishimoto, Kazuki Takahashi, Shingo Nakayamada, Yoshiya Tanaka
{"title":"Sarilumab治疗风湿性多肌痛的有效性和安全性:FIRST注册的回顾性研究","authors":"Naoaki Ohkubo, Yusuke Miyazaki, Satoshi Kubo, Ippei Miyagawa, Koshiro Sonomoto, Yoshino Inoue, Yurie Satoh-Kanda, Hiroaki Tanaka, Masanobu Ueno, Atsushi Nagayasu, Takafumi Aritomi, Ryuichiro Kanda, Yuya Fujita, Masashi Funada, Hidenori Sakai, Kiyotake Yoshioka, Mayu Nishimoto, Kazuki Takahashi, Shingo Nakayamada, Yoshiya Tanaka","doi":"10.1093/mr/roag030","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To evaluate the effectiveness of sarilumab in patients with polymyalgia rheumatica (PMR) who were clinically assessed as having coexisting rheumatoid arthritis.</p><p><strong>Methods: </strong>Using data from the FIRST registry, a cohort of patients initiating molecular targeted therapy for rheumatoid arthritis, we identified cases from 2003 to April 2024 in which sarilumab was introduced as the first biologic agent and PMR was concurrently diagnosed. As a control group, we selected patients hospitalized for a PMR flare during the same period who received the standard of care without biologic therapy. The primary outcome was the clinical PMR Activity Score at 52 weeks post-treatment initiation.</p><p><strong>Results: </strong>Among 5645 registered cases, 67 patients were identified as having PMR with coexisting rheumatoid arthritis and received sarilumab as their initial biologic therapy. The control group comprised 76 patients treated with conventional therapy alone. The 52-weeks continuation rate of sarilumab was 77.5%, indicating high treatment persistence. At 52 weeks, clinical PMR Activity Score scores decreased in both groups. Logistic regression analysis using low disease activity at 52 weeks as the outcome revealed sarilumab use as a significant predictor. After adjusting for baseline differences using inverse probability weighting based on propensity scores, the sarilumab group showed a significantly greater reduction in the clinical PMR Activity Score compared to the standard of care group.</p><p><strong>Conclusions: </strong>These findings suggest that sarilumab may have the potential to improve disease activity in polymyalgia rheumatica compared to conventional therapy.</p>","PeriodicalId":18705,"journal":{"name":"Modern Rheumatology","volume":" ","pages":"1046-1054"},"PeriodicalIF":2.1000,"publicationDate":"2026-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effectiveness and safety of sarilumab in polymyalgia rheumatica: A retrospective study of the FIRST registry.\",\"authors\":\"Naoaki Ohkubo, Yusuke Miyazaki, Satoshi Kubo, Ippei Miyagawa, Koshiro Sonomoto, Yoshino Inoue, Yurie Satoh-Kanda, Hiroaki Tanaka, Masanobu Ueno, Atsushi Nagayasu, Takafumi Aritomi, Ryuichiro Kanda, Yuya Fujita, Masashi Funada, Hidenori Sakai, Kiyotake Yoshioka, Mayu Nishimoto, Kazuki Takahashi, Shingo Nakayamada, Yoshiya Tanaka\",\"doi\":\"10.1093/mr/roag030\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>To evaluate the effectiveness of sarilumab in patients with polymyalgia rheumatica (PMR) who were clinically assessed as having coexisting rheumatoid arthritis.</p><p><strong>Methods: </strong>Using data from the FIRST registry, a cohort of patients initiating molecular targeted therapy for rheumatoid arthritis, we identified cases from 2003 to April 2024 in which sarilumab was introduced as the first biologic agent and PMR was concurrently diagnosed. As a control group, we selected patients hospitalized for a PMR flare during the same period who received the standard of care without biologic therapy. The primary outcome was the clinical PMR Activity Score at 52 weeks post-treatment initiation.</p><p><strong>Results: </strong>Among 5645 registered cases, 67 patients were identified as having PMR with coexisting rheumatoid arthritis and received sarilumab as their initial biologic therapy. The control group comprised 76 patients treated with conventional therapy alone. The 52-weeks continuation rate of sarilumab was 77.5%, indicating high treatment persistence. At 52 weeks, clinical PMR Activity Score scores decreased in both groups. Logistic regression analysis using low disease activity at 52 weeks as the outcome revealed sarilumab use as a significant predictor. After adjusting for baseline differences using inverse probability weighting based on propensity scores, the sarilumab group showed a significantly greater reduction in the clinical PMR Activity Score compared to the standard of care group.</p><p><strong>Conclusions: </strong>These findings suggest that sarilumab may have the potential to improve disease activity in polymyalgia rheumatica compared to conventional therapy.</p>\",\"PeriodicalId\":18705,\"journal\":{\"name\":\"Modern Rheumatology\",\"volume\":\" \",\"pages\":\"1046-1054\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2026-11-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Modern Rheumatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/mr/roag030\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"RHEUMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Modern Rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/mr/roag030","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:评估sarilumab在临床评估为共存类风湿性关节炎(RA)的风湿性多肌痛(PMR)患者中的有效性。方法:使用来自FIRST注册中心的数据,这是一个开始分子靶向治疗RA的患者队列,我们确定了2003年至2024年4月期间引入sarilumab作为首个生物药物并同时诊断PMR的病例。作为对照组,我们选择在同一时期因PMR发作住院的患者,他们接受标准治疗(SoC)而不接受生物治疗。主要终点是治疗开始后52周的临床多肌痛风湿病活动评分(clinp - pmr - as)。结果:在5645例登记病例中,67例患者被确定为PMR合并RA,并接受了sarilumab作为初始生物治疗。对照组76例患者单独接受常规治疗。沙伐单抗的52周延续率为77.5%,表明治疗持续性高。52周时,两组临床- pmr - as评分均下降。采用52周低疾病活动度作为结果的Logistic回归分析显示,使用沙伐单抗是一个显著的预测因子。在使用基于倾向评分的逆概率加权调整基线差异后,与SoC组相比,sarilumab组显示出更大的clini - pmr - as降低。结论:这些发现表明,与传统治疗相比,sarilumab可能具有改善风湿性多肌痛疾病活动性的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Effectiveness and safety of sarilumab in polymyalgia rheumatica: A retrospective study of the FIRST registry.

Objectives: To evaluate the effectiveness of sarilumab in patients with polymyalgia rheumatica (PMR) who were clinically assessed as having coexisting rheumatoid arthritis.

Methods: Using data from the FIRST registry, a cohort of patients initiating molecular targeted therapy for rheumatoid arthritis, we identified cases from 2003 to April 2024 in which sarilumab was introduced as the first biologic agent and PMR was concurrently diagnosed. As a control group, we selected patients hospitalized for a PMR flare during the same period who received the standard of care without biologic therapy. The primary outcome was the clinical PMR Activity Score at 52 weeks post-treatment initiation.

Results: Among 5645 registered cases, 67 patients were identified as having PMR with coexisting rheumatoid arthritis and received sarilumab as their initial biologic therapy. The control group comprised 76 patients treated with conventional therapy alone. The 52-weeks continuation rate of sarilumab was 77.5%, indicating high treatment persistence. At 52 weeks, clinical PMR Activity Score scores decreased in both groups. Logistic regression analysis using low disease activity at 52 weeks as the outcome revealed sarilumab use as a significant predictor. After adjusting for baseline differences using inverse probability weighting based on propensity scores, the sarilumab group showed a significantly greater reduction in the clinical PMR Activity Score compared to the standard of care group.

Conclusions: These findings suggest that sarilumab may have the potential to improve disease activity in polymyalgia rheumatica compared to conventional therapy.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Modern Rheumatology
Modern Rheumatology RHEUMATOLOGY-
CiteScore
4.90
自引率
9.10%
发文量
146
审稿时长
1.5 months
期刊介绍: Modern Rheumatology publishes original papers in English on research pertinent to rheumatology and associated areas such as pathology, physiology, clinical immunology, microbiology, biochemistry, experimental animal models, pharmacology, and orthopedic surgery. Occasional reviews of topics which may be of wide interest to the readership will be accepted. In addition, concise papers of special scientific importance that represent definitive and original studies will be considered. Modern Rheumatology is currently indexed in Science Citation Index Expanded (SciSearch), Journal Citation Reports/Science Edition, PubMed/Medline, SCOPUS, EMBASE, Chemical Abstracts Service (CAS), Google Scholar, EBSCO, CSA, Academic OneFile, Current Abstracts, Elsevier Biobase, Gale, Health Reference Center Academic, OCLC, SCImago, Summon by Serial Solutions
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书